BB Holdings LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$5,783	2
2022	Research	$14,258	3
2021	Research	$810,629	3
2020	Research	$38,290	4
2019	Research	$98,439	14

Breakdown

Who paid Research payments · program years 2019–2023

AstraZeneca UK Limited $824,788 6 payments
Shire North American Group Inc $60,567 10 payments
AstraZeneca Pharmaceuticals LP $54,905 6 payments
Eli Lilly and Company $22,270 2 payments
Takeda Pharmaceuticals U.S.A., Inc. $2,870 1 payment
Mitsubishi Tanabe Pharma Development America, Inc. $2,000 1 payment

Studies the money was for Research payments · program years 2019–2023

A Phase I Open-Label Randomized 2-Treatment 2-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule $818,132 2 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $61,561 10 payments
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 Pvp-Iodine 0.6 and Dexamethasone 0.1 Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis $37,214 3 payments
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 Pvp-Iodine 0.6 and Dexamethasone 0.1 Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis $23,353 7 payments
An Open Label, Long Term, Safety Study of Lasmiditan 100 MG and 200 MG in the Acute Treatment of Migraine Gladiator $22,270 2 payments
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 (Pvp-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis $2,870 1 payment
A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women $2,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.